Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
In October, AMCP joined other pharmacy organizations in supporting the Pharmacist's Fundamental Responsibilities and Rights released by APhA and the National Alliance of State Pharmacy Associations (NASPA). These principles focus on pharmacists' responsibilities and the workplace conditions necessary to fulfill those responsibilities.
AMCP submitted comments on the proposed FDA Prescription Drug User Fee Act Reauthorization commitment letter, supporting the agency's plans to increase resources for approval of cell and gene therapies and continued exploration of uses for real-world evidence in regulatory decision-making.
Pharmacy associations offer condolences to families of pharmacist and two others killed in Maryland.
On Sept. 14, AMCP joined a Medicaid stakeholder letter urging Congress to include language that requires 12-month continuous eligibility for children on Medicaid and the Children’s Health Insurance Program (CHIP) in the reconciliation bill.
Letter requests an immediate amendment to the PREP Act declaration on COVID-19, which would allow pharmacists to order and administer REGEN-COV and future authorized products for the treatment of COVID-19.
On July 28, AMCP provided comments on PQA's prospective strategic and broad-reaching goals.
On July 28, AMCP signed a Medicare Part D stakeholder letter urging HHS to extend the Enhanced Medication Therapy Management (EMTM) Model which is currently set to expire on December 31, 2021.
Joint Statement in Support of COVID-19 Vaccine Mandates for All Workers in Health and Long-Term Care
On July 26, AMCP joined other health care organizations in a joint statement in support of COVID-19 Vaccine mandates for all workers in health and long-term care.
AMCP submitted comments on a Office of Management and Budget request for information on advancing equity in underserved communities through government.
On June 14, AMCP submitted comments on the Medicare Part D Medication Therapy Management Program's Standardized Format for the comprehensive medication review.
On May 25, AMCP joined Medicare stakeholder organizations in thanking Congressional members for introducing the Pharmacy and Medically Underserved Areas Enhancement Act (H.R. 2759/S.1362).
AMCP sent a letter to the Department of Health and Human Services Office of the Inspector General on changes to the federal anti-kickback statute.
